A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).

Exclusion Criteria

• •Patients with the following diseases or symptoms are excluded: Space-occupying lesion in brain. Life-threatening opportunistic infection at time of entry into trial. History of major psychiatric illness prior to 1977 or time of initial exposure to HIV, if that is known.
• •Patients with the following diseases or symptoms are excluded: Space-occupying lesion in brain. Life-threatening opportunistic infection at time of entry into trial. History of major psychiatric illness prior to 1977 or time of initial exposure to HIV, if that is known.
• •Excluded within 4 weeks of study entry:
• •Antiretroviral agents. Anticancer treatments. Psychoactive agents.
• •Excluded within 4 months of study entry:
• •Suramin.
• •Avoid: Antiretroviral medication. Immunomodulating medication. Psychoactive medication.
• •Excluded within 4 weeks of study entry:
• •Radiation.
• •Breast-feeding
• •Positive pregnancy test
• •Pregnant
• •No abstinence or no agreement to use barrier methods of birth control / contraception during the study